Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

11.5%

3 terminated out of 26 trials

Success Rate

87.0%

+0.5% vs benchmark

Late-Stage Pipeline

12%

3 trials in Phase 3/4

Results Transparency

40%

8 of 20 completed with results

Key Signals

8 with results87% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (4)
P 1 (7)
P 2 (8)
P 3 (3)

Trial Status

Completed20
Terminated3
Withdrawn2
Unknown1

Trial Success Rate

87.0%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT03198286Not ApplicableCompleted

Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors

NCT02164461Phase 1Completed

Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer

NCT05025748Not ApplicableCompleted

Ask Questions (ASQ):Implementation of a Communication Intervention

NCT01992861Terminated

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

NCT00577317Phase 3Terminated

Flexitouch® Home Maintenance Therapy or Standard Home Maintenance Therapy in Treating Patients With Lower-Extremity Lymphedema Caused by Treatment for Cervical Cancer, Vulvar Cancer, or Endometrial Cancer

NCT03112668Not ApplicableCompleted

Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners

NCT01019278Phase 2Withdrawn

Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes

NCT02880007Phase 2Completed

Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer

NCT01266447Phase 2Completed

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT00262821Phase 3Terminated

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

NCT00416455Phase 1Completed

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

NCT03469531Phase 2Unknown

Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

NCT01098630Completed

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

NCT00941070Phase 2Completed

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

NCT00460356Completed

Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes

NCT00017004Phase 3Completed

Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia

NCT00559377Phase 2Completed

FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer

NCT00897442Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

NCT01155258Phase 1Completed

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00054444Phase 1Completed

Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer

Scroll to load more

Research Network

Activity Timeline